Ocular Microbiology and Immunology Group
Back to OMIG Main Page

2017 Agenda and Abstracts | < Previous Next >

2017 OMIG Abstract 17

3 Month Continuous Release of Therapeutic Levels of Latanaprost
from Episcleral Collagen Wafers In The Rabbit
Richard A Eiferman, MD, FACS¹, Dale P Devore, PhD^2
1University Of Louisville, Louisville, Kentucky;
²DV Consulting, Boston, Massachusetts

Purpose:  To demonstrate a novel drug delivery system for sustained release of latanaprost in vivo.

Method: 25 ug of 3H latanaprost and 500 ug of ”cold” latanaprost were added to a specially prepared cross-linked collagen wafer.  The rabbits were anesthetized and an incision was made in the conjunctiva.  The wafers were inserted superiorly onto the sclera of albino rabbits in one eye; the other eye served as a control.  The incisions were closed with cautery.  Animals were sacrificed at 30, 60 and 90 days.  Test samples from aqueous (100µL), tear film (filter paper swipe), and saliva (filter paper swipe), blood (1mL), cornea, vitreous, and iris/ciliary body and placed in a liquid scintillation counter.

Results: 

Conclusion: There was continuous release of latanaprost at therapeutic levels from the episcleral collagen implant.  This method could eliminate the need for self administered eye drops to treat glaucoma. 

Disclosure:  P

2017 Agenda and Abstracts | < Previous Next >